Safety, Tolerability, and Efficacy of Deferasirox in MDS
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
Open label, single arm study on Deferasirox treatment in MDS patients with chronic
transfusional hemosiderosis.
Patients receive daily oral dosis of Deferasirox in order to eliminate the quantity of iron
administered during transfusions and, if needed, to reduce the overload of already present
iron.
After an screening phase in which patients are evaluated according to eligibility criteria, a
one year treatment phase foresees monthly visits to evaluate safety and efficacy signs.